Eva-Juliane Vollstedt

Eva-Juliane Vollstedt

Auto-generated profile, based on publicly available information

Eva-Juliane Vollstedt

Institute of Neurogenetics, University of Luebeck

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2020 in Movement Disorders
Verified
Journal Article
Open access
PDF file
VSVolha Skrahina
Volha Skrahina
HGHanaa Gaber
Hanaa Gaber
EVEva‐Juliane Vollstedt
Eva‐Juliane Vollstedt
TFToni M. Förster
Toni M. Förster
TUTatiana Usnich
Tatiana Usnich
TGthe ROPAD Study Group
the ROPAD Study Group
Background: Genetic stratification of Parkinson's disease (PD) patients facilitates gene‐tailored research studies and clinical trials. The objective of this study was to describe the design of and the initial data from the Rostock International Parkinson's Disease (ROPAD) study, an epidemiological observational study aiming to genetically characterize ~10,000 participants.Methods: Recruitment criteria included (1) clinical diagnosis of PD, (2) relative of participant with a reportable LRRK2 variant, or (3) North African Berber or Ashkenazi Jew. DNA analysis involved up to 3 successive steps: (1) variant (LRRK2) and gene (GBA) screening, (2) panel sequencing of 68 PD‐linked genes, and (3) genome sequencing.Results: Initial data based on the first 1360 participants indicated that the ROPAD enrollment strategy revealed a genetic diagnostic yield of ~14% among a PD cohort from tertiary referral centers.Conclusions: The ROPAD screening protocol is feasible for high‐throughput genetic characterization of PD participants and subsequent prioritization for gene‐focused research efforts and clinical trials. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

24 January 2023 in Movement Disorders
Verified
Journal Article
Open access
EVEva‐Juliane Vollstedt
Eva‐Juliane Vollstedt
SSSusen Schaake
Susen Schaake
KLKatja Lohmann
Katja Lohmann
SPShalini Padmanabhan
Shalini Padmanabhan
ABAlexis Brice
Alexis Brice
TGthe MJFF Global Genetic Parkinson's Disease Study Group
the MJFF Global Genetic Parkinson's Disease Study Group
Background: As gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial‐ready cohorts is limited.Objective: The objectives are to (1) establish an international cohort of affected and unaffected individuals with PD‐linked variants; (2) provide harmonized and quality‐controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD.Methods: We conducted a worldwide, systematic online survey to collect individual‐level data on individuals with PD‐linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ‐1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed.Results: We collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ‐1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published.Conclusions: Within the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD‐linked variants; (2) provide harmonized and quality‐controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene‐targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

2 June 2019 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
EVEva‐Juliane Vollstedt
Eva‐Juliane Vollstedt
MKMeike Kasten
Meike Kasten
CKChristine Klein
Christine Klein
MGMJFF Global Genetic Parkinson's Disease Study Group
MJFF Global Genetic Parkinson's Disease Study Group

15 April 2022 in Science Advances
Verified
Journal Article
Open access
CKChristine Klein
Christine Klein
MBMax Borsche
Max Borsche
ABAlexander Balck
Alexander Balck
BFBandik Föh
Bandik Föh
JRJohann Rahmöller
Johann Rahmöller
AKAlexander Katalinic
Alexander Katalinic
With newly rising coronavirus disease 2019 (COVID-19) cases, important data gaps remain on (i) long-term dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rates in fixed cohorts (ii) identification of risk factors, and (iii) establishment of effective surveillance strategies. By polymerase chain reaction and antibody testing of 1% of the local population and >90,000 app-based datasets, the present study surveilled a catchment area of 300,000 inhabitants from March 2020 to February 2021. Cohort (56% female; mean age, 45.6 years) retention was 75 to 98%. Increased risk for seropositivity was detected in several high-exposure groups, especially nurses. Unreported infections dropped from 92 to 29% during the study. “Contact to COVID-19–affected” was the strongest risk factor, whereas public transportation, having children in school, or tourism did not affect infection rates. With the first SARS-CoV-2 cohort study, we provide a transferable model for effective surveillance, enabling monitoring of reinfection rates and increased preparedness for future pandemics.

3 October 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EVEva-Juliane Vollstedt
Eva-Juliane Vollstedt
HMHarutyun Madoev
Harutyun Madoev
AAAnna Aasly
Anna Aasly
AAAzlina Ahmad-Annuar
Azlina Ahmad-Annuar
BABashayer Al-Mubarak
Bashayer Al-Mubarak
CKChristine Klein
Christine Klein
Parkinson’s disease (PD) is the fastest-growing neurodegenerative disorder, currently affecting ~7 million people worldwide. PD is clinically and genetically heterogeneous, with at least 10% of all cases explained by a monogenic cause or strong genetic risk factor. However, the vast majority of our present data on monogenic PD is based on the investigation of patients of European White ancestry, leaving a large knowledge gap on monogenic PD in underrepresented populations. Gene-targeted therapies are being developed at a fast pace and have started entering clinical trials. In light of these developments, building a global network of centers working on monogenic PD, fostering collaborative research, and establishing a clinical trial-ready cohort is imperative. Based on a systematic review of the English literature on monogenic PD and a successful team science approach, we have built up a network of 59 sites worldwide and have collected information on the availability of data, biomaterials, and facilities. To enable access to this resource and to foster collaboration across centers, as well as between academia and industry, we have developed an interactive map and online tool allowing for a quick overview of available resources, along with an option to filter for specific items of interest. This initiative is currently being merged with the Global Parkinson’s Genetics Program (GP2), which will attract additional centers with a focus on underrepresented sites. This growing resource and tool will facilitate collaborative research and impact the development and testing of new therapies for monogenic and potentially for idiopathic PD patients.

15 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
JJJohanna Junker
Johanna Junker
LLLara M. Lange
Lara M. Lange
EVEva-Juliane Vollstedt
Eva-Juliane Vollstedt
KRKarisha Roopnarain
Karisha Roopnarain
MDMaria Leila M. Doquenia
Maria Leila M. Doquenia
T(the Global Parkinson’s Genetics Program (GP2)
the Global Parkinson’s Genetics Program (GP2)
Until recently, about three-quarters of all monogenic Parkinson's disease (PD) studies were performed in European/White ancestry, thereby severely limiting our insights into genotype-phenotype relationships at global scale. The first systematic approach to embrace monogenic PD worldwide, The Michael J. Fox Foundation Global Monogenic PD (MJFF GMPD) Project, contacted authors of publications reporting individuals carrying pathogenic variants in known PD-causing genes. In contrast, the Global Parkinson's Genetics Program's (GP2) Monogenic Network took a different approach by targeting PD centers not yet represented in the medical literature. Here, we describe combining both efforts in a "merger project" resulting in a global monogenic PD cohort with build-up of a sustainable infrastructure to identify the multi-ancestry spectrum of monogenic PD and enable studies of factors modifying penetrance and expression of monogenic PD. This effort demonstrates the value of future research based on team science approaches to generate comprehensive and globally relevant results.